NervGen Pharma Corp.
NGENF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.27 | -0.05 | 0.24 | -0.10 |
| FCF Yield | -2.21% | -1.49% | -2.03% | -1.67% |
| EV / EBITDA | -37.20 | -35.79 | -31.38 | -29.83 |
| Quality | ||||
| ROIC | 212.16% | 751.59% | -410.20% | 0.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.28 | 0.40 | 1.04 | 0.43 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -45.10% | 11.01% | -12.54% | 36.39% |
| Safety | ||||
| Net Debt / EBITDA | 1.84 | 2.42 | 2.39 | 2.53 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |